Match!
Clinical Colorectal Cancer
IF
3.18
Papers
1118
Papers 1124
1 page of 113 pages (1,124 results)
Newest
#1Rebecca A. Snyder (ECU: East Carolina University)
#2Keith Francis Fournier (University of Texas MD Anderson Cancer Center)H-Index: 13
Last.George J. Chang (University of Texas MD Anderson Cancer Center)H-Index: 46
view all 5 authors...
Source
#1Kelsey Lau-Min (UPenn: University of Pennsylvania)
#2Preeti Prakash (BCM: Baylor College of Medicine)
Last.Benjamin Leon Musher (Baylor University)
view all 6 authors...
ABSTRACT BACKGROUND Metastatic colorectal cancer (mCRC) outcomes continue to improve, but they vary significantly by race and ethnicity. We hypothesize that these disparities arise from unequal access to care. MATERIALS AND METHODS The Harris Health System (HHS) is an integrated health delivery network that provides medical care to the underserved, predominantly minority population of Harris County, Texas. As the largest HHS facility and an affiliate of Baylor College of Medicine’s Dan L. Duncan...
Source
#1Lorenzo FornaroH-Index: 17
#2Francesco Leone (UNITO: University of Turin)H-Index: 20
Last.Francesco MontagnaniH-Index: 8
view all 25 authors...
ABSTRACT Background FOLFIRINOX is an option for fit patients with metastatic (MPC) and locally advanced unresectable (LAPC) pancreatic cancer. However, no criteria reliably identify patients with better outcome. Patients and Methods We investigated putative prognostic factors among 137 MPC/LAPC patients treated with triplet chemotherapy. Association with 6-month survival status (primary endpoint) was assessed by multivariate logistic regression models. A nomogram predicting the risk of death at ...
Source
#1Jianwei ZhangH-Index: 2
#2Meijin HuangH-Index: 12
Last.Yanhong DengH-Index: 10
view all 21 authors...
Abstract Purpose Although neoadjuvant chemo-radiotherapy (CRT) achieves low local recurrence rates in locally advanced rectal cancer (LARC), it raises a lot of concerns about long-term anal and sexual functions. We explored the efficacy of preoperative chemotherapy with mFOLFOXIRI in patients with LARC. Patients and Methods Patients with LARC evaluated by pelvic magnetic resonance imaging (MRI) were enrolled in this trial. All received four to six cycles of mFOLFOXIRI. MRI was performed to asses...
Source
#1Elena BolzacchiniH-Index: 2
#2Giovanna LuchenaH-Index: 4
Last.Monica GiordanoH-Index: 18
view all 3 authors...
Source
#1Paul Cavallaro (Harvard University)H-Index: 6
#2Liliana Bordeianou (Harvard University)H-Index: 24
Last.Rocco Ricciardi (Harvard University)H-Index: 26
view all 9 authors...
Abstract Background The impact of primary tumor site on overall survival in stage IV colorectal cancer (CRC) patients with single-organ metastases to the liver or lung has not been studied. Furthermore, the prognostic significance of commonly tested genetic variants such as KRAS mutation and microsatellite instability (MSI) are not well-described in this population. Methods This National Cancer Database was used to identify 38,328 patients with CRC that presented with synchronous metastases to t...
Source
#1Rachel M. Lee (Emory University)H-Index: 1
#2Mohammad Y. Zaidi (Emory University)H-Index: 4
Last.Maria C. Russell (Emory University)H-Index: 16
view all 28 authors...
Abstract Background Radiographic prediction of PCI can improve patient selection for cytoreductive surgery. We aimed to determine the correlation of CT-predicted PCI (CT-PCI) and MRI-predicted PCI (MRI-PCI) with intraoperative-PCI, and if a preoperative-PCI cutoff is associated with incomplete cytoreduction. Patients and Methods Patients from the US HIPEC Collaborative (2000-17) with appendiceal, colorectal, or peritoneal mesothelioma (PM) histology who underwent cytoreductive surgery were inclu...
Source
#1Mehmet Akce (Emory University)H-Index: 2
#2Renjian Jiang (Emory University)H-Index: 4
Last.Bassel F. El-Rayes (Emory University)H-Index: 29
view all 8 authors...
Abstract Background Small bowel adenocarcinomas (SBAs) are rare tumors. Management of SBA is extrapolated from colorectal cancer treatments. Recent evidence suggests that the biology and molecular features of SBA differ from colorectal cancer. The aim of this study was to evaluate the management and outcome of SBA patients. Patients and Methods The National Cancer Data Base (NCDB) was queried for patients with SBA between 2004 and 2013 using ICD-O-3 histology code 8140/3 and topography codes C17...
Source
#1Julien Taieb (Paris V: Paris Descartes University)H-Index: 46
#2M. GeisslerH-Index: 11
Last.Marie-Rose PeetersH-Index: 43
view all 10 authors...
Abstract Background There is no standardised assessment of symptomatic events in metastatic colorectal cancer (mCRC), despite disease symptoms impacting treatment decisions. Data from 3 first-line panitumumab in mCRC trials were retrospectively analysed to assess whether early tumour shrinkage (ETS) and depth of response (DpR) are associated with time to occurrence of tumour-related symptoms. Patients and Methods Patients with RAS wild-type mCRC from PRIME, PEAK and study ‘314 were included. ETS...
Source
#1Nirit Yarom (TAU: Tel Aviv University)H-Index: 7
#2Gillian Gresham (Johns Hopkins University)H-Index: 10
Last.Derek J. Jonker (Ottawa Hospital)H-Index: 25
view all 4 authors...
Abstract Background: KRAS mutations occur in 40% of colorectal cancers (CRCs), affecting the efficacy of agents targeting the epidermal growth factor receptor. However, the effect of KRAS mutation status on the activity of non-epidermal growth factor receptor-targeting chemotherapy has not been fully elucidated. The aim of the present study is to evaluate the effect of KRAS status on the activity of different chemotherapeutic regimens. Patients and Methods: A retrospective chart review of chemot...
1 CitationsSource
12345678910
Top fields of study
Oncology
Colorectal cancer
General surgery
Medicine
Pharmacology